B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience

B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience

ObjectivesThe aim of the study was to describe a cohort of B-cell-depleted immunocompromised (IC) patients with prolonged or relapsing COVID-19 treated with monotherapy or combination therapy.MethodsThis is a multicenter observational retrospective study conducted on IC patients consecutively hospit...

Full description

Bibliographic Details
Main Authors: Alessandra D’Abramo, Serena Vita, Alessia Beccacece, Assunta Navarra, Raffaella Pisapia, Francesco Maria Fusco, Giulia Matusali, Enrico Girardi, Fabrizio Maggi, Delia Goletti, Emanuele Nicastri, ImmunoCOVID team, Tommaso Ascoli Bartoli, Nazario Bevilacqua, Angela Corpolongo, Patrizia De Marco, Maria Letizia Giancola, Gaetano Maffongelli, Andrea Mariano, Laura Scorzolini, Claudia Palazzolo, Silvia Rosati, Virginia Tomassi, Francesca Faraglia, Lavinia Fabeni, Martina Rueca, Silvia Meschi, Cesare Ernesto Maria Gruber
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Medicine
Subjects:
persistent SARS-CoV-2 infection
B-cell depleted
combined therapy
antiviral
MoAbs
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1344267/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1344267/full

Similar Items